Nkarta, Inc.

NasdaqGS NKTX

Nkarta, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 61,710,110

Nkarta, Inc. Shares (Diluted, Weighted) is 61,710,110 for the Trailing 12 Months (TTM) ending September 30, 2024, a 26.08% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Nkarta, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 48,947,023, a 23.59% change year over year.
Nkarta, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 39,604,816, a 20.86% change year over year.
Nkarta, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 32,770,348, a 31.32% change year over year.
Nkarta, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 24,954,933.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: NKTX

Nkarta, Inc.

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court
Employees	159
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends

Past 5 years